InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the
research and development of novel, cannabinoid-based drug therapies, today announces the filing of a provisional patent application pertaining to the Company’s proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature. |